论文部分内容阅读
目的:观察细辛脑注射液雾化吸入对支气管哮喘急性发作期的临床疗效。方法:将支气管哮喘急性发作期患者随机分为对照组和治疗组(各60例),对照组给予传统治疗和沙丁胺醇、布地奈德联合雾化吸入;治疗组在前者治疗基础上将雾化液中的沙丁胺醇和布地奈德剂量减半,同时加入细辛脑注射液。将两组治疗72h前后的临床症状、体征、动脉氧分压(PaO2)及第1s用力呼气容积(FEV1)、呼气峰流速(PEF)变化进行比较。结果:对照组和治疗组总体有效率分别为76.7%、95.0%,差异存在统计学意义(χ2=7.535,P=0.024)。与对照组比较,治疗组的PaO2、FEV1及PEF指标改善更为明显(t=2.035~3.163,均P<0.05)。结论:细辛脑注射液雾化吸入对支气管哮喘急性发作期患者疗效确切,与沙丁胺醇和布地奈德联合雾化具有协同作用,安全方便,可以较快缓解症状。
Objective: To observe the clinical effect of Asarum Injection on aerosol inhalation in acute attack of bronchial asthma. Methods: The patients with acute exacerbation of bronchial asthma were randomly divided into control group and treatment group (60 cases in each group). The control group was given traditional treatment with salbutamol and budesonide inhalation. In the treatment group, In salbutamol and budesonide dose halved, while adding asarone injection. The clinical symptoms, signs, arterial oxygen pressure (PaO2), forced expiratory volume (FEV1), and peak expiratory flow (PEF) were compared between the two groups before and after treatment for 72 hours. Results: The overall effective rates of the control group and the treatment group were 76.7% and 95.0%, respectively, with statistical significance (χ2 = 7.535, P = 0.024). Compared with the control group, the PaO2, FEV1 and PEF indexes of the treatment group improved more obviously (t = 2.035 ~ 3.163, all P <0.05). Conclusion: Asarone Injection is effective in treating patients with acute exacerbation of bronchial asthma. It has a synergistic effect with salbutamol and budesonide in combination with nebulization, which is safe and convenient and can relieve symptoms more quickly.